12月31日 - ** Axsome Therapeutics AXSM.O股价盘前上涨2.2%至152美元
** 制药商称美国 FDA 已接受其治疗阿尔茨海默病躁动的药物 AXS-05 的上市申请
** 阿尔茨海默氏症患者的躁动是一种常见的情绪困扰症状，表现为坐立不安、踱步、言语失控或身体攻击，通常由疼痛、生活习惯改变、困惑或不知所措引发。
** 美国食品和药物管理局已授予该申请 "优先审查 "标签，该标签专门授予那些可显著改善严重疾病的有效性或安全性的药物。
** 卫生监管机构将于 2026 年 4 月 30 日对该药物做出决定 - AXSM
** 截至上次收盘，股价年累计上涨 75.8%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.